3-bromo-2-methylpyrazolo[1,5-a]pyrimidine, 95.0%, 250mg

N-([1,1'-Biphenyl]-4-yl)-N-(4-bromophenyl)-9,9-dimethyl-9H-fluoren-2-amine, 97%, 10g

1-Butyl-3-methylimidazolium Trifluoroacetate>97.0%(T)25g

GC-Kapillarsäule ROTI®Cap-1701, L 50 m, Ø-Innen 0,32 mm, Filmd. 1,00 µm, 1 Stück

4-((2-Hydroxyethyl)(methyl)amino)benzaldehyde, 95.0%, 25g

5-Chloro-2,4-difluorobenzenesulfonamide, 97%, 5g

2-Fluoro-4-formylbenzoic acid, 95.0%, 500mg

n-Hexyl sulfonyl chloride, 95.0%, 250mg

ETHYL 8-METHYL-1,4-DIOXASPIRO[4.5]DECANE-8-CARBOXYLATE, 95.0%, 10g

2-(4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl)ethano-hydrazide, 2g

5,7-dimethyl-2-piperazin-1-yl-1,3-benzothiazole hydrochloride, 95.0%, 250mg

5-FLUORO-2-METHOXYPYRIDIN-4-OL, 95.0%, 1g

Thalidomide-NH-PEG4-COOH, 100mg